Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AUTL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AUTO CAR T cell therapy | Patients Followed for up to 15 Years Following Their First Dose of… | Phase 2 · NCT03628612 | Enrolling by invitation |
| Obecabtagene Autoleucel | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1/2 · NCT04404660 | Active not recruiting |
| Autologous BCMA/TACI-targeted CAR T Cells AUTO2 | Multiple Myeloma | Phase 1/2 · NCT03287804 | Terminated |
| Autologous Anti-CD19/CD22 CAR T-cells AUTO3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1/2 · NCT03287817 | Terminated |
| AUTO3 (CD19/22 CAR T cells | B Acute Lymphoblastic Leukemia | Phase 1/2 · NCT03289455 | Completed |
| Anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing… | T Cell Non-Hodgkin Lymphoma | Phase 1/2 · NCT03590574 | Terminated |
| Out-of-specification obecabtagene autoleucel | Lymphoblastic Leukemia, Acute, Adult | N/A · NCT06799221 | Available |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AUTL holds $248.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $21.8M/quarter from operations, an estimated runway of 34.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Accordingly, management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUTL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| MAK Capital Fund LP | 5%+ holder (13G) | 30,528,859 | 11.46% | 2026-09-30 |
| BXLS V - Autobahn L.P. | 5%+ holder (13D) | 20,485,611 | 7.69% | 2026-11-06 |
| Renata Kellnerova | 5%+ holder (13D) | 14,782,275 | 5.55% | 2026-08-27 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 13,750,000 | 5.16% | 2026-09-30 |
| Christian Itin Chief Executive Officer, Director |
Insider | 1,116,009 | 0.42% | 2026-03-18 |
| Christopher Andrew Vann Chief Operating Officer |
Insider | 152,211 | 0.06% | 2026-03-18 |
| John E Berriman Director |
Insider | 136,331 | 0.05% | 2026-03-18 |
| Cintia Piccina U.S. CCO & Country Gen Manager · +60,000 options |
Insider | 13,287 | 0.00% | 2026-09-01 |
| Christopher Michael James Williams Chief Business Officer |
Insider | 8,198 | 0.00% | 2026-03-18 |
Share count 266,340,330 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUTL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →